Skip to main content

Holiday schedule

Our Patient Service Centers will be closed on Monday, May 27, 2024 for the Memorial Day holiday. Have a healthy, happy holiday.


Decades of experience translates into unrivaled expertise interpreting results

Myasthenia gravis (MG) is an autoimmune disorder characterized by muscle weakness that ranges from mild to severe for multiple muscle groups. MG is characterized by mild to severe muscle weakness and most commonly involves acetylcholine receptor (AChR) antibodies.

Detection of 5 known antibodies can help guide treatment options

A misdiagnosis is more likely when not screening for LRP4 antibodies 

Our comprehensive myasthenia gravis portfolio includes testing for LRP4 antibodies.
  • LRP4 antibodies are believed to be the third-leading cause of MG6
  • Most LRP4-positive patients improve after standard MG therapy4
  • LRP4 is most prevalent in ocular MG7

Why order myasthenia gravis testing from Quest


1. Rivner MH, Pasnoor M, Dimachkie MM, et al. Muscle-specific tyrosine kinase and myasthenia gravis owing to other antibodies. Neurol Clin. 2018;36(2):293-310. doi:10.1016/j.ncl.2018.01.004

2. Suzuki S, Utsugisawa K, Nagane Y, et al. Three types of striational antibodies in myasthenia gravis. Autoimmune Dis. 2011;740583. doi:10.4061/2011/740583

3. Haven TR, Astill ME, Pasi BM, et al. An algorithm for acetylcholine receptor antibody testing in patients with suspected myasthenia gravis. Clin Chem.

2010;56(6):1028-1029. doi:10.1373/clinchem.2009.140392

4. Rivner MH, Quarles BM, Pan JX, et al. Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: a multicenter study. Muscle Nerve. 2020;62(3):333-343. doi:10.1002/mus.26985

5. antibodies. Accessed August 27, 2020.

6. Zouvelou V, Zisimopoulou P, Rentzos M, et al. Double seronegative myasthenia gravis with anti-LRP4 antibodies. Neuromuscul Disord. 2013;23(7):568-570. doi:10.1016/j.nmd.2013.03.013

7. Phillips WD, Vincent A. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms. F1000Res. 2016;5(F1000 Faculty Rev):1513. doi:10.12688/f1000research.8206.1

Join our email community

Get the very latest news and information from Quest Advanced® Neurology.

Sign up